ANNUAL INDEX

Volume 2, January-December, 1967

Abbreviations: Ja—January; F—February; Mr—March; Ap—April; My—May; Je—June; Jl—July; Ag—August; S—September; O—October; N—November; D—December.

ABC's of generics, the. J. K. Weston, M.D. Je 27

AMA provides new services for p&t committees. J. S. Chisholm. N 64

ANAGNOSTOPOULOS, L. D., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Treatment of status epilepticus, with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40

ANDERSON, R. W. and B. F. Holland. Selecting hospital disinfectant agents. S 41

Antimetabolites, purine. W. F. Scott. Jl 31

APPLEZWEIG, N. Sooner or later. F 49

ARCHAMBAULT, G. F. Medicare and pharmacy services. Ja 23; Investigational drugs and the law. Ap 25; Clinical performance standards or specifications for medications. My 21

BARCHIESI, A., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin K. Ap 21; Report of the committee on therapeutic agents on the dextrans. N 60

BARKMAN, R. Pharmacy and therapeutics committees and drug information centers in Sweden. F 57

BERGMAN, J. J., M.D., et al. Report of the committee on therapeutic agents on the dextrans. N 60

BOGASH, R. C. and U. F. Caruso. Iodine content of contrast media. My 46

BOGASH, R. C. Editorial. Ja 82; F 98; Mr 82; Ap 70; My 74; Je 62; S 102; O 78

BOOK REVIEW. Ja. 58; F 96; My 71; S 30

CANADA, A. T., Jr., and M. K. Yim. The problem of drug hypersensitivities in hospitals. N 47

CARUSO, U. F. and R. C. Bogash. Iodine content of contrast media. My 46

CARLIN, H. S. Policies and procedures for use of pharmaceuticals. O 51; N 51; D 22

CHISHOLM, J. S. Medicare—the turning point. Ja. 30; The physician-pharmacist team. Jl 44; The ama provides new services for p&t committees. N 64

Clinical performance standards or specifications for medications. G. F. Archambault. My 21

Coagulation achieved during warfarin therapy, the effect of phenobarbital administration on the control of. D. S. Robinson, M.D., and M. G. MacDonald, M.D. Ap 43

CONN, J. C., Jr., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Treatment of status epilepticus with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40; Report of the committee on therapeutic agents on the dextrans. N 60

Container requirements, light and tight. My 28

Coronary vasodilators, report of the committee on therapeutic agents on. G. C. Henegar, M.D., C. O. Dummett, J. B. Hammond, M.D., L. J. Kettel, M.D., S. H. Steiner, M.D. and A. Kravitz. Je 43

DBS: small agency with a big job. J. D. Snyder. Ag 50

Dentistry, rationale of drug therapy in. A. G. Zupko, Ph.D. F 68

Dextrans, report of the committee on therapeutic agents on the. L. J. Kettel, M.D., J. J. Bergan, M.D., A. Barchiesi, M.D., J. C. Conn, Jr., M.D., R. H. Parker, M.D. and A. Kravitz. N 60

DIA progress. R. L. Marlin. Ap 50

Diazepam, treatment of status epilepticus with parenteral. L. J. Kettel, M.D., L. D. Anagnostopoulos, M.D., R. H. Parker, M.D., J. C. Conn, Jr., M.D., R. Spehlmann, M.D. and A. Kravitz. Ag 48

DINEL, B. and C. J. Latiolais. Drug interaction—enzyme induction. O 35

Disinfectant agents, selecting hospital. B. F. Holland and R. W. Anderson. S 41

DONDIS, E. H., Ph.D., L. E. Weeks and W. H. Smith, Ph.D. Drug usage and drug availability. Ja 45

Drug efficacy studies. J.D. Snyder. O 60

Drug hypersensitivities in hospitals, the problem of. A. T. Canada, Jr. and M. K. Yim. N 47

Drug innovations of 1966. J. T. Hicks, Ph.D., M.D. Mr 35; Ap 30; My 30; Je 30; Jl 42

Drug interaction—enzyme induction. B. Dinel and C. J. Latiolais. O 35

"Drug literature program" offers hospitals worldwide data. J. D. Snyder. Mr 46

Drugs in the hospital. J. L. Goddard, M.D. F 35

Drugs, lyophilization of. Sr. Mary Cabrini, S.S.J. Ag 35

DRUG RECALLS. Ja 78; F 78; Mr 67; Ap 54; My 66; Je 46; Jl 18; Ag 18; S 32; O 26; N 34; D 16

DRUG REVIEW. James T. Hicks, Ph.D., M.D. Mercury (Hg). Ja 70; Librium. F 88; Equanil (Meprobamate). Mr 74; Gold compounds. My 58; Etrafon (Perphenazine-amitriptyline hydrochloride). Je 54; Choloxin (sodium hydrochloride). Jl 58; Darvon (propoxyphene hydrochloride). Ag 24; Placidyl (ethchlorvynol). S 23; LMD (dextran 40). O 18; Cannabis. N 42

DRUG THERAPY ABSTRACTS. Clifton J. Latiolais. My 48; Je 57; Jl 50; Ag 56; S 88; O 68; N 68; D 36

Drug unitage, interpretations of. R. L. Lantos. S 54; O 44

Drug usage and drug availability. L. E. Weeks, E. H. Dondis, Ph.D., and W. H. Smith, Ph.D. Ja 45

Drugs, profile of prescription. J. D. Snyder. D 32

Drugs affecting laboratory values. J. T. Hicks, Ph.D., M.D. D 19

DUMMETT C. O., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

EDITORIAL. Robert C. Bogash. Ja 82; F 98; Mr 82; Ap 70; My 74; Je 62; S 102; O 78

EDITORIAL. Charles U. Letourneau, M.D., B.C.L. Ag 62; N 76; D 48

EDITORIAL. James D. Snyder. Jl 62

Efficacy studies, drug. J. D. Snyder. O 60

Enzyme induction, drug interaction. B. Dinel and C. J. Latiolais. O 35

Ethacrynic acid, report of the committee on therapeutic agents on. N. M. Simon, M.D., M. E. Gantt, M.D., J. C. Conn, Jr., M.D., L. J. Kettel, M.D., R. H. Parker, M.D., L. D. Anagnostopoulos, M.D. and A. Kravitz. O 40

Expectorants. H. B. Richerson, M.D. S 66

FDA APPROVED DRUGS. Ja 80; F 82; Mr 16; Ap 38; My 64; Je 52; Jl 60; Ag 30; S 36; O 31

FILER, L. J., M.D. Iron requirements in infancy and childhood. Ag 41

GANTT, M. E., M.D., et al. Report of the committee on therapeutic agents on ethacrynic acid. O 40

Generics, the abc's of. J. K. Weston, M.D. Je 27

GODDARD, J. L., M.D. Drugs in the hospital. F 35

GROLLMAN, A., Ph.D., M.D. Iatrogenic disease: the penalty for medical progress. Mr 45

HAMMOND, J. B., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

Health centers, neighborhood. J. D. Snyder. Jl 36

HELLER, F. N., M.D. Post-operative respiratory depression. My 39

HENEGAR, G. C., M.D., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

Heparin therapy, guidelines for. J. C. Hoak, M.D. D 34

HICKS, J. T., Ph.D., M.D. Drug innovations of 1966. Mr 35; Ap 30; My 30; Je 30; Jl 42; Drugs affecting laboratory values. D 19

HICKS, J. T., Ph.D., M.D. Drug Review. Ja 70; F 88; Mr 74; My 58; Je 54; Jl 58; Ag 24; S 23; O 18; N 42

HOAK, J. C., M.D. Guidelines for heparin therapy. D 34

HOLLAND, B. F. and R. W. Anderson. Selecting hospital disinfectant agents. S 41

Hospital disinfectant agents, selecting. B. F. Holland and R. W. Anderson. S 41

Hypersensitivities in hospitals, the problem of drug. A. T. Canada, Jr. and M. K. Yim. N 47

Iatrogenic disease: the penalty for medical progress. A. Grollman, Ph.D., M.D. Mr 45

Impact of government and private health insurance. F 81

Intravenous therapy. J. T. Williams, M.D., and D. F. Moravec. Ja 35

Investigational drugs and the law. G. F. Archambault. Ap 25

Please turn to page 46.

ANNUAL INDEX

Volume 2, January-December, 1967

Abbreviations: Ja—January; F—February; Mr—March; Ap—April; My—May; Je—June; Jl—July; Ag—August; S—September; O—October; N—November; D—December.

ABC's of generics, the. J. K. Weston, M.D. Je 27

AMA provides new services for p&t committees. J. S. Chisholm. N 64

ANAGNOSTOPOULOS, L. D., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Treatment of status epilepticus, with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40

ANDERSON, R. W. and B. F. Holland. Selecting hospital disinfectant agents. S 41

Antimetabolites, purine. W. F. Scott. Jl 31

APPLEZWEIG, N. Sooner or later. F 49

ARCHAMBAULT, G. F. Medicare and pharmacy services. Ja 23; Investigational drugs and the law. Ap 25; Clinical performance standards or specifications for medications. My 21

BARCHIESI, A., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin K. Ap 21; Report of the committee on therapeutic agents on the dextrans. N 60

BARKMAN, R. Pharmacy and therapeutics committees and drug information centers in Sweden. F 57

BERGMAN, J. J., M.D., et al. Report of the committee on therapeutic agents on the dextrans. N 60

BOGASH, R. C. and U. F. Caruso. Iodine content of contrast media. My 46

BOGASH, R. C. Editorial. Ja 82; F 98; Mr 82; Ap 70; My 74; Je 62; S 102; O 78

BOOK REVIEW. Ja. 58; F 96; My 71; S 30

CANADA, A. T., Jr., and M. K. Yim. The problem of drug hypersensitivities in hospitals. N 47

CARUSO, U. F. and R. C. Bogash. Iodine content of contrast media. My 46

CARLIN, H. S. Policies and procedures for use of pharmaceuticals. O 51; N 51; D 22

CHISHOLM, J. S. Medicare—the turning point. Ja. 30; The physician-pharmacist team. Jl 44; The ama provides new services for p&t committees. N 64

Clinical performance standards or specifications for medications. G. F. Archambault. My 21

Coagulation achieved during warfarin therapy, the effect of phenobarbital administration on the control of. D. S. Robinson, M.D., and M. G. MacDonald, M.D. Ap 43

CONN, J. C., Jr., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Treatment of status epilepticus with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40; Report of the committee on therapeutic agents on the dextrans. N 60

Container requirements, light and tight. My 28

Coronary vasodilators, report of the committee on therapeutic agents on. G. C. Henegar, M.D., C. O. Dummett, J. B. Hammond, M.D., L. J. Kettel, M.D., S. H. Steiner, M.D. and A. Kravitz. Je 43

DBS: small agency with a big job. J. D. Snyder. Ag 50

Dentistry, rationale of drug therapy in. A. G. Zupko, Ph.D. F 68

Dextrans, report of the committee on therapeutic agents on the. L. J. Kettel, M.D., J. J. Bergan, M.D., A. Barchiesi, M.D., J. C. Conn, Jr., M.D., R. H. Parker, M.D. and A. Kravitz. N 60

DIA progress. R. L. Marlin. Ap 50

Diazepam, treatment of status epilepticus with parenteral. L. J. Kettel, M.D., L. D. Anagnostopoulos, M.D., R. H. Parker, M.D., J. C. Conn, Jr., M.D., R. Spehlmann, M.D. and A. Kravitz. Ag 48

DINEL, B. and C. J. Latiolais. Drug interaction—enzyme induction. O 35

Disinfectant agents, selecting hospital. B. F. Holland and R. W. Anderson. S 41

DONDIS, E. H., Ph.D., L. E. Weeks and W. H. Smith, Ph.D. Drug usage and drug availability. Ja 45

Drug efficacy studies. J.D. Snyder. O 60

Drug hypersensitivities in hospitals, the problem of. A. T. Canada, Jr. and M. K. Yim. N 47

Drug innovations of 1966. J. T. Hicks, Ph.D., M.D. Mr 35; Ap 30; My 30; Je 30; Jl 42

Drug interaction—enzyme induction. B. Dinel and C. J. Latiolais. O 35

"Drug literature program" offers hospitals worldwide data. J. D. Snyder. Mr 46

Drugs in the hospital. J. L. Goddard, M.D. F 35

Drugs, lyophilization of. Sr. Mary Cabrini, S.S.J. Ag 35

DRUG RECALLS. Ja 78; F 78; Mr 67; Ap 54; My 66; Je 46; Jl 18; Ag 18; S 32; O 26; N 34; D 16

DRUG REVIEW. James T. Hicks, Ph.D., M.D. Mercury (Hg). Ja 70; Librium. F 88; Equanil (Meprobamate). Mr 74; Gold compounds. My 58; Etrafon (Perphenazine-amitriptyline hydrochloride). Je 54; Choloxin (sodium hydrochloride). Jl 58; Darvon (propoxyphene hydrochloride). Ag 24; Placidyl (ethchlorvynol). S 23; LMD (dextran 40). O 18; Cannabis. N 42

DRUG THERAPY ABSTRACTS. Clifton J. Latiolais. My 48; Je 57; Jl 50; Ag 56; S 88; O 68; N 68; D 36

Drug unitage, interpretations of. R. L. Lantos. S 54; O 44

Drug usage and drug availability. L. E. Weeks, E. H. Dondis, Ph.D., and W. H. Smith, Ph.D. Ja 45

Drugs, profile of prescription. J. D. Snyder. D 32

Drugs affecting laboratory values. J. T. Hicks, Ph.D., M.D. D 19

DUMMETT C. O., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

EDITORIAL. Robert C. Bogash. Ja 82; F 98; Mr 82; Ap 70; My 74; Je 62; S 102; O 78

EDITORIAL. Charles U. Letourneau, M.D., B.C.L. Ag 62; N 76; D 48

EDITORIAL. James D. Snyder. Jl 62

Efficacy studies, drug. J. D. Snyder. O 60

Enzyme induction, drug interaction. B. Dinel and C. J. Latiolais. O 35

Ethacrynic acid, report of the committee on therapeutic agents on. N. M. Simon, M.D., M. E. Gantt, M.D., J. C. Conn, Jr., M.D., L. J. Kettel, M.D., R. H. Parker, M.D., L. D. Anagnostopoulos, M.D. and A. Kravitz. O 40

Expectorants. H. B. Richerson, M.D. S 66

FDA APPROVED DRUGS. Ja 80; F 82; Mr 16; Ap 38; My 64; Je 52; Jl 60; Ag 30; S 36; O 31

FILER, L. J., M.D. Iron requirements in infancy and childhood. Ag 41

GANTT, M. E., M.D., et al. Report of the committee on therapeutic agents on ethacrynic acid. O 40

Generics, the abc's of. J. K. Weston, M.D. Je 27

GODDARD, J. L., M.D. Drugs in the hospital. F 35

GROLLMAN, A., Ph.D., M.D. Iatrogenic disease: the penalty for medical progress. Mr 45

HAMMOND, J. B., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

Health centers, neighborhood. J. D. Snyder. Jl 36

HELLER, F. N., M.D. Post-operative respiratory depression. My 39

HENEGAR, G. C., M.D., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43

Heparin therapy, guidelines for. J. C. Hoak, M.D. D 34

HICKS, J. T., Ph.D., M.D. Drug innovations of 1966. Mr 35; Ap 30; My 30; Je 30; Jl 42; Drugs affecting laboratory values. D 19

HICKS, J. T., Ph.D., M.D. Drug Review. Ja 70; F 88; Mr 74; My 58; Je 54; Jl 58; Ag 24; S 23; O 18; N 42

HOAK, J. C., M.D. Guidelines for heparin therapy. D 34

HOLLAND, B. F. and R. W. Anderson. Selecting hospital disinfectant agents. S 41

Hospital disinfectant agents, selecting. B. F. Holland and R. W. Anderson. S 41

Hypersensitivities in hospitals, the problem of drug. A. T. Canada, Jr. and M. K. Yim. N 47

Iatrogenic disease: the penalty for medical progress. A. Grollman, Ph.D., M.D. Mr 45

Impact of government and private health insurance. F 81

Intravenous therapy. J. T. Williams, M.D., and D. F. Moravec. Ja 35

Investigational drugs and the law. G. F. Archambault. Ap 25

Please turn to page 46.

Continued from page **44.**

Iodine content of contrast media. U. F. Caruso and R. C. Bogash. My 46
Iron requirements in infancy and childhood. L. J. Filer, M.D. Ag 41

KETTEL, L. J., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43; Treatment of status epilepticus with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40; Report of the committee on therapeutic agents on the dextrans. N 60
KRAVITZ, A., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Report of the committee on therapeutic agents on coronary vasodilators. Je 43; Treatment of status epilepticus with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40; Report on the committee on therapeutic agents on the dextrans. N 60
KURLAND, H. D., M.D., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38
KWAAN, H., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21

Laboratory values, drugs affecting. J. T. Hicks, Ph.D., M.D. D 19
LANTOS, R. L. Interpretations of drug unitage. S 54; O 44
LATIOLAIS, C. J. Drug Therapy Abstracts. My 48; Je 57; Jl 50; Ag 56; S 88; O 68; N 68; D 36
LATIOLAIS, C. J. and B. Dinel. Drug interaction—enzyme induction. O 35
LAW. Charles L. Letourneau, M.D., B.C.L. Anaphylatic reaction to penicillin. Ja 18; Bladder irrigation with zephiran. F 86; Chloromycetin—duty to warn. Mr 79; Side effects of pyribenzamine—two views. Ap 56; Duty to warn. Jl 12; Charges against pharmacist need not be stated with technical nicety. Ag 32; Strict liability of manufacturer. S 80; Physician's duty to warn. N 30
Law, investigational drugs and the. G. F. Archambault. Ap 25
LETTERS. F 24; My 62; N 73
LETOURNEAU, C. U., M.D., B.C.L. Editorial. Ag 62; N 76; D 48
LETOURNEAU, C. U., M.D. B.C.L. Law. Ja 18; F 86; Mr 79; Ap 56; Jl 12; Ag 32; S 80; N 30
LETOURNEAU, C. U., M.D., B.C.L. Reader response to hospital formulary management. S 47
LSD and the law. M. E. Trout, M.D. S 70
Lyophilization of drugs. Sr. Mary Cabrini, S.S.J. Ag 35

MacDONALD, M. G., M.D. and D. S. Robinson, M.D. The effect of phenobarbital administration on the control of coagulation achieved during warfarin therapy. Ap 43
MARLIN, R. L. DIA progress. Ap 50
MASCIOLI, M. and J. D. Snyder. The role of the formulary committee in poison control. Ja 60
"Medicaid:" its impact on drug usage patterns. J. D. Snyder. Je 36
Medicare and pharmacy services. G. F. Archambault. Ja 23
Medicare—the turning point. J. S. Chisholm. Ja 30
MEYERS, E. L. Extemporaneous mixing of parenteral medications. Je 32
MORAVEC, D. F. and J. T. Williams, M.D. Intravenous therapy. Ja 35

NEW DRUG NAMES. Ja 66; F 28; Mr 62; Ap 52; My 56
NEWSLETTER. Ja 10; F 16; Mr 14; Ap 16; My 12; Je 18; Jl 26; Ag 8; S 14; O 14; N 18; D 12
New success in treating bedsores. Ap 14
NIH pharmacology-toxicology program, the. J. D. Snyder. S 76

Organophosphorus insecticides, poisoning with. W. J. R. Taylor, M.D. Mr 53

P&T committee policies. R. L. Ravin. S 48
Parenteral medications, extemporaneous mixing of. E. L. Meyers. Je 32
PARKER, R. H., M.D., et al. Report of the committee on therapeutic agents on penicillins, polymyxins and cephalosporins. F 38; Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21; Treatment of status epilepticus with parenteral diazepam. Ag 48; Report of the committee on therapeutic agents on ethacrynic acid. O 40; Report of the committee on therapeutic agents on the dextrans. N 60
Penicillins, polymyxins and cephalosporins, report of the committee on therapeutic agents on. G. C. Henegar, M.D., C. O. Dummett, L. J. Kettel, M.D., R. H. Parker, M.D., H. D. Kurland, M.D. and A. Kravitz. F 38
Pharmacology-toxicology program, the nih. J. D. Snyder. S 76
Pharmacy and therapeutics committees and drug information centers in Sweden. R. Barkman. F 57
Phenobarbital administration on the control of coagulation achieved during warfarin therapy, the effect of. D. S. Robinson, M.D. and M. G. MacDonald, M.D. Ap 43
Physician-pharmacist team, the. J. S. Chisholm. Jl 44
Physician's right to prescribe, the. H. Turkel, M.D. Mr 23
PIERRE, R. J., M.D., et al. Report of the committee on therapeutic agents on the use and abuse of vitamin k. Ap 21
Policies and procedures for use of pharmaceuticals. H. S. Carlin. O 51; N 51; D 22
Post-operative respiratory depression. F. N. Heller, M.D. My 39
Prescription drugs, profile of. J. D. Snyder. D 32
Purine antimetabolites. W. F. Scott. Jl 31

Rationale of drug therapy in dentistry. A. G. Zupko, Ph.D. F 68
RAVIN, R. L. P&T committee policies. S 48
Reader response to hospital formularly management. C. U. Letourneau, M.D., B.C.L. S 47
RICHERSON, H. B., M.D. Expectorants. S 66
ROBINSON, D. S., M.D. and M. G. MacDonald, M.D. The effect of phenobarbital administration on the control of coagulation achieved during warfarin therapy. Ap 43
Role of the formulary committee in poison control the. J. D. Snyder and M. Mascioli. Ja 60

SCOTT, W. F. Purine antimetabolities. Jl 31
SIMON, N. M., M.D., et al. Report of the committee on therapeutic agents on ethacrynic acid. O 40
SISTER MARY CABRINI, S.S.J. Lyophilization of drugs. Ag 35
SMITH, W. H., Ph.D., L. E. Weeks and E. H. Dondis, Ph. D. Drug usage and drug availability. Ja 45
SNYDER, J. D. "Drug literature program" offers hospitals worldwide data. Mr 46; "Medicaid:" its impact on drug usage patterns. Je 36; Neighborhood health centers. Jl 36; DBS: small agency with a big job. Ag 50; The nih pharmacology-toxicology program. S 76; Drug efficacy studies. O 60; Profile of prescription drugs. D 32
SNYDER, J. D. Editorial. Jl 62
SNYDER J. D. Washington Scene. Ja 6; F 10; Mr 8; Ap 10; My 8; Je 10; Jl 8; Ag 12; S 8; O 8; N 12; D 8
SNYDER, J. D. and M. Mascioli. The role of the formulary committee in poison control. Ja 60
Sooner or later. N. Applezweig. F 49
SPEHLMANN, R., M.D., et al. Treatment of status epilepticus with parenteral diazepam. Ag 48
Status epilepticus with parenteral diazepam, treatment of. L. J. Kettel, M.D., L. D. Anagnostopoulos, M.D., R. H. Parker, M.D., J. C. Conn, Jr., M.D., R. Spehlmann, M.D. and A. Kravitz. Ag 48
STEINER, S. H., M.D., et al. Report of the committee on therapeutic agents on coronary vasidilators. Je 43

TAYLOR, W. J. R., M.D. Poisoning with organophosphorus insecticides. Mr 53
TROUT, M. E., M.D., LL.B. LSD and the law. S 70
TURKEL, H., M.D. The physician's right to prescribe. Mr 23

Vitamin k, report of the committee on therapeutic agents on the use and abuse of. G. C. Henegar, M.D., L.D. Anagnostopoulos, M.D., L. J. Kettle, M.D., R. H. Parker, M.D., J. C. Conn, Jr., M.D., H. Kwaan, M.D., J. B. Hammond, M.D., R. J. Pierre, M.D., A Barchiesi, M.D. and A. Kravitz. Ap 21

Warfarin therapy, the effect of phenobarbital administration on the control of coagulation achieved during. D. S. Robinson, M.D. and M. G. MacDonald, M.D. Ap 43
WASHINGTON SCENE. James D. Snyder. Ja 6; F 10; Mr 8; Ap 10; My 8; Je 10; Jl 8; Ag 12; S 8; N 12; D 8
WEEKS, L. E., E. H. Dondis, Ph.D. and W. H. Smith, Ph.D. Drug usage and drug availability. Ja 45
WESTON, J. K., M.D. The abc's of generics. Je 27
WILLIAMS, J. T., M.D. and D. F. Moravec. Intravenous therapy. Ja 35

YIM, M. K. and A. T. Canada, Jr. The problem of drug hypersensitivities in hospitals. N 47

ZUPKO, A. G., Ph.D. Rationale of drug therapy in dentistry. F 68